SABS SAB Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SABS

Price (delayed)

$4.1

Market cap

$37.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.64

Enterprise value

-$12.83M

Highlights
SAB Biotherapeutics's equity has surged by 84% YoY
SAB Biotherapeutics's net income has shrunk by 125% YoY and by 55% QoQ
SAB Biotherapeutics's revenue has shrunk by 91% YoY and by 45% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of SABS
Market
Shares outstanding
9.23M
Market cap
$37.82M
Enterprise value
-$12.83M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
10.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.73
Earnings
Revenue
$2.24M
EBIT
-$41.88M
EBITDA
-$38.13M
Free cash flow
-$25.27M
Per share
EPS
-$7.64
Free cash flow per share
-$4.58
Book value per share
$10.95
Revenue per share
$0.41
TBVPS
$15.2
Balance sheet
Total assets
$83.94M
Total liabilities
$26.64M
Debt
$5.91M
Equity
$57.3M
Working capital
$48.09M
Liquidity
Debt to equity
0.1
Current ratio
5.45
Quick ratio
5.23
Net debt/EBITDA
1.33
Margins
EBITDA margin
-1,703.1%
Gross margin
100%
Net margin
-1,884.5%
Operating margin
-1,700.6%
Efficiency
Return on assets
-88.6%
Return on equity
-144.7%
Return on invested capital
-193%
Return on capital employed
-57.3%
Return on sales
-1,870.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SABS stock price

How has the SAB Biotherapeutics stock price performed over time
Intraday
1.23%
1 week
-2.38%
1 month
-10.87%
1 year
-52.87%
YTD
-40.36%
QTD
-10.87%

Financial performance

How have SAB Biotherapeutics's revenue and profit performed over time
Revenue
$2.24M
Gross profit
$2.24M
Operating income
-$38.08M
Net income
-$42.19M
Gross margin
100%
Net margin
-1,884.5%
The company's net margin has shrunk by 184% QoQ
The operating margin has dropped by 157% since the previous quarter
SAB Biotherapeutics's net income has shrunk by 125% YoY and by 55% QoQ
SAB Biotherapeutics's revenue has shrunk by 91% YoY and by 45% QoQ

Growth

What is SAB Biotherapeutics's growth rate over time

Valuation

What is SAB Biotherapeutics stock price valuation
P/E
N/A
P/B
0.37
P/S
10.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.73
The EPS has shrunk by 77% YoY and by 34% QoQ
SAB Biotherapeutics's equity has surged by 84% YoY
The P/B is 74% below the last 4 quarters average of 1.4
SAB Biotherapeutics's revenue has shrunk by 91% YoY and by 45% QoQ
The P/S is 16% above the last 4 quarters average of 8.3

Efficiency

How efficient is SAB Biotherapeutics business performance
The ROS has shrunk by 185% QoQ
SABS's ROA has plunged by 172% YoY and by 28% from the previous quarter
The ROE has plunged by 170% YoY and by 20% from the previous quarter
SAB Biotherapeutics's ROIC has plunged by 64% from the previous quarter

Dividends

What is SABS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SABS.

Financial health

How did SAB Biotherapeutics financials performed over time
The company's total assets has surged by 196% QoQ and by 65% YoY
The total liabilities has surged by 104% since the previous quarter and by 34% year-on-year
The company's debt is 90% lower than its equity
SAB Biotherapeutics's equity has surged by 84% YoY
SABS's debt to equity has dropped by 67% since the previous quarter and by 47% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.